课题基金 / 基金详情

B2036 PEG IN ACROMEGALY

B2036 PEG IN ACROMEGALY
B2036 肢端肥大症中的 PEG
批准号：
6264638
负责人：
DAVID L KLEINBERG
金额：
$2.1万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264638
关键词：
acromegaly biological signal transduction clinical research drug adverse effect drug screening /evaluation endocrine disorder chemotherapy hormone inhibitor hormone receptor human subject human therapy evaluation insulinlike growth factor placebos polyethylene glycols skeletal disorder chemotherapy somatotropin

项目摘要

项目成果

DAVID L KLEINBERG的其他基金

相似基金

相关文献

中文摘要
翻译
这项关于B2036-PEG的随机、双盲、安慰剂对照研究将试图确定该药物在肢端肥大症患者中的耐受性和有效性。B2036-PEG是一种生长激素受体拮抗剂，它将可逆地与生长激素受体结合，阻断信号转导，导致循环中IGF-1的减少。
英文摘要
This randomized, double-blind, placebo controlled, study of B2036-PEG will attempt to determine the tolerability and efficacy of this drug in the subjects with acromegaly. B2036-PEG is a growth hormone receptor antagonist which will reversibly bind to the growth hormone receptor, blocking signal tranduction, and lead to reductions in circulating IGF-1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SURGICAL DEBULKING PLUS OCTREOTIDE VERSUS OCTREOTIDE ALONE IN ACROMEGALY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
PREVALENCE OF GROWTH HORMONE DEFICIENCY & RANGES OF IGF-1 IN NORMAL ELDERLY
Prevalence of Growth Hormone Deficiency & Ranges of IGF-1 in Normal Elderly
海外基金